A. Lembo

Publications511
h-index65
Citations15,916
Highly Influential Citations529
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Camilleri
  • 1,534 Publications • 62,880 Citations
  • N. Talley
  • 1,993 Publications • 90,128 Citations
  • W. Chey
  • 767 Publications • 20,267 Citations
  • D. Drossman
  • 530 Publications • 39,478 Citations
  • Publications
  • Influence
Rifaximin therapy for patients with irritable bowel syndrome without constipation.
TLDR
Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.
View on PubMed
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
TLDR
The criteria developed through the Rome process, currently in its third iteration, have been those most widely employed in clinical trials and, therefore, most relevant to any review of the literature on the management of these disorders.
View on Nature
American Gastroenterological Association medical position statement on constipation.
TLDR
Current recommendations will relate to (1) rational and, where possible, more judicious diagnostic approaches and (2) more rational and efficacious therapies that ill improve symptoms, both of which should have beneficial scal and logistic impacts on the health care system.
View on PubMed
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
TLDR
BT is a useful, inexpensive, simple and safe diagnostic test in the evaluation of common gastroenterology problems and should help to standardize the indications, preparation, performance and interpretation of BT in clinical practice and research.
View on Wolters Kluwer
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
TLDR
Whether open-label placebo is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS) is tested and placebos administered without deception may be an effective treatment for IBS.
View PDF
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
TLDR
Linaclotide significantly improved abdominal pain and bowel symptoms associated with IBS-C for at least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of linaclotides during the RW period.
View on Nature
Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety
TLDR
Linaclotide 290 μg once daily significantly improved abdominal and bowel symptoms associated with IBS-C over 26 weeks of treatment, and Statistically significant differences from placebo were observed for responder and continuous end points over 26 Weeks of treatment.
View on Wolters Kluwer
Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis
TLDR
Probiotics are effective treatments for IBS, although which individual species and strains are the most beneficial remains unclear, and the efficacy of all three therapies in CIC is also uncertain.
View on Nature
Chronic constipation.
TLDR
Constipation is more prevalent in women than in men, in nonwhites than in white persons, in children than in adults, 6 and in elderly than in younger adults.
View on PubMed
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
TLDR
Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diarrhea in men and women, with sustained efficacy over 6 months in patients who received the 100-mg dose twice daily.
View on PubMed
...
...